Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
₩ 14130
Key Takeaways
Risk factor
Significant default risk
Data is available to registered users only
Data is available to registered users only
Profitability factor
Weak margins and returns
Data is available to registered users only
Data is available to registered users only
About
Green Cross Holdings Corporation operates as a biotechnology company. The company provides plasma derivatives, prescription drugs, over the counter drugs, and hunter syndrome drugs; and vaccines for hemorrhagic fever, varicella, hepatitis-B, and flu. It also researches and develops oncology, immunology, and cell therapy products; and offers recombinant protein treatment for hemophilia. The company has partnerships...
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. Specifically, the stock is fairly valued on P/E, overvalued on EV/EBITD
Data is available to registered users only
Buy
Sell